Phase I/IIa

Quotient Clinical has a strong heritage of expertise in First-in-Human (FIH) studies augmented by specialist early development services, including unique capabilities to speed the development process from FIH through to Proof of Concept.

We conduct the full range of human pharmacology studies on all types of drug candidate with objectives to assess tolerability, define/describe PK and PD and explore drug metabolism and drug interactions. These studies can be augmented with a range of clinical services to help identify “developability” issues prior to embarking on Phase I and help to guide decision making on further clinical development strategies. For more information see drug product optimisation and ¹⁴C enabled drug development services

All Phase I study designs can be accommodated and we can provide references from customers in global pharmaceutical companies through to small “virtual” biotechs worldwide.